Cells

Primary Caprine Testicular Microvascular Endothelial Cells (TMEC)

Primary Rat Spinal Cord Perineurial Fibroblasts (SCPF)

Please note this product may be subject to fees, we invite you to contact your local office. PRAME TCR CD8⁺ NFAT-Luciferase Reporter Jurkat Cell Line was generated from T Cell Receptor (TCR) Knockout NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #78556) by overexpression of human CD8 (NM_001768.6) and a PRAME (Preferentially Expressed Antigen in Melanoma)-directed TCR using lentiviral transduction (CD8a Lentivirus #78648 and PRAME-Specific TCR Lentivirus #78959). This PRAME TCR specifically recognizes an antigen PRAME peptide, amino acids peptide 425-433 (SLLQHLIGL).

Please note this product may be subject to fees, we invite you to contact your local office. The Vγ4Vδ1 TCR NFAT-Luciferase Reporter Jurkat Cell Line was generated from the T Cell Receptor (TCR) Knockout NFAT Luciferase Reporter Jurkat Cell Line (#78556) by overexpression of human Vγ4Vδ1 TCR using lentiviral transduction (with Vγ4Vδ1 TCR Lentivirus #78986). This cell line was functionally validated with a TCR Vδ1 agonist antibody.

Please note this product may be subject to fees, we invite you to contact your local office. The MDA-MB-436 cell line is derived from a human breast adenocarcinoma. This cell line is characterized by its triple-negative breast cancer (TNBC) phenotype, lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Such characteristics make it an invaluable model for studying TNBC, a particularly aggressive and difficult-to-treat subtype of breast cancer. The cells exhibit an epithelial morphology and are known for their robust proliferative capacity in vitro. Genetically, MDA-MB-436 cells harbor mutations in key cancer-related genes, including BRCA1 and TP53. The BRCA1 mutation is of particular interest, as it mirrors the genetic alterations found in a subset of hereditary breast cancers. This makes MDA-MB-436 a crucial tool for investigating the mechanisms underlying BRCA1-associated tumorigenesis and for testing potential t

The Transduction Control (Tet-On) iPS Cell Pool is an iPS (induced pluripotent stem) cell pool that was generated via lentiviral transduction with Expression Negative Control Lentivirus (Inducible Tet-On) (#82290). This cell pool can be used as control for Cas9 Inducible (Tet-On) iPS Cell Pool (BPS Bioscience #78845).

This cell line was generated by transducing the TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line (BPS Bioscience #78556) with lentiviruses (CD4 Lentivirus, Bioscience #78987) to overexpress human CD4 (NM_000616.5). To achieve knockout of TCR (T Cell Receptor), the TRAC (T-Cell Receptor Alpha Constant) and TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from Jurkat cells that stably expressed firefly luciferase under the control of NFAT response elements. TCRα/β knockout in the TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line was confirmed by both genomic sequencing and flow cytometry. Expression of CD4 in CD4⁺ TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line was confirmed by flow cytometry. The cell line does not respond to anti-CD3 agonist antibodies, as opposed to the parental NFAT-Luciferase Reporter Jurkat Cell Line (BPS Bioscience #60621). This cell line has been functionally

IL-23 Responsive STAT3 Luciferase Reporter HEK293 Cell Line is an engineered HEK293 cell line expressing firefly luciferase under the control of STAT3 response element, and human IL-23 receptor complex (IL12Rβ1 NM_005535.3 and IL23R NM_144701.3). With this cell line, IL-23 activity can be monitored by measuring luciferase activity. The functionality of the IL-23 Responsive STAT3 Luciferase Reporter HEK293 Cell Line was validated in dose-response assays using a recombinant human interleukin 23 (human IL-23; p19 + p40), inhibition assays using the anti-IL-23 antibodies Ustekinumab and Guselkumab, as well as a Janus Kinase inhibitor, Ruxolitinib.  

NF-κB TWO-Luciferase Reporter HEK293 Cell Line is a HEK293 cell line designed to monitor cell viability alongside NF-κB (nuclear factor Kappa B) activity. It contains a firefly luciferase reporter driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. In addition, this cell line constitutively expresses Renilla Luciferase under the control of a CMV promoter, which can be used to determine cell viability. This cell has been validated with TNFα (tumor necrosis factor alpha), and the inhibitor IKK-16 dihydrochloride.